"Very near future" . . . . .17 May 2026 09:39
This is a LinkedIn post that Christina Dorris (CelLBx Health's recently hired US VP of Commercials) liked . . . . .
Whether it perhaps hints at Roche being added to the list of runners & riders of potential top ten Pharma that Collins mentioned - time will tell.
"The future of oncology diagnostics is not about selling isolated tests.
It is about building integrated ecosystems.
Roche’s recent moves to strengthen its oncology solutions portfolio are another clear signal that the market is moving in this direction.
For years, many diagnostics companies have positioned themselves around a single technology:
NGS, liquid biopsy, pathology, imaging, companion diagnostics, software, or data.
But oncology care does not work in isolated silos.
A patient journey may involve tissue diagnosis, genomic profiling, therapy selection, response monitoring, resistance detection, MRD assessment, imaging, pathology review, and longitudinal clinical data.
The companies that will create real strategic value are not necessarily those with one excellent test.
They will be those capable of connecting multiple layers of information into a clinically usable workflow.
This has several implications.
First, diagnostics companies need to think beyond the assay.
Clinical value increasingly depends on workflow integration, interpretation, reporting, accessibility, and physician adoption.
Second, data becomes as important as the sample.
The ability to connect molecular, pathological, imaging, and clinical information will become a major differentiator.
Third, commercial models will evolve.
Hospitals, labs, and clinical networks may increasingly prefer integrated solutions rather than fragmented vendor relationships.
Fourth, partnerships will become essential.
No single company can own every layer of the oncology pathway.
Strategic collaborations between diagnostics, pharma, digital pathology, AI, and clinical networks will define the next phase of precision oncology.
For smaller and mid-sized diagnostic companies, this is both a warning and an opportunity.
The warning: a great test alone may not be enough.
The opportunity: if positioned correctly, specialized technologies can become valuable components of larger oncology ecosystems.
In precision oncology, the question is no longer only:
“Is the test analytically good?”
It is becoming:
“Can this solution fit into a broader clinical decision-making system and change how patients are managed?”
That is where the next wave of value will be created."
Whether it's via CRO's, sizeable US Healthcare Companies, Solaris/MidLantic as just one example, marketing collaborations with the likes of Illumina, Qiagen, Myriad or front & centre & at the coal face with The Royal Marsden this MedTech minnow appears to have some life in it still.
Sign In
Follow the stocks
